Table 6.
The Primers Designed for the Regions Tested on Chromosome 18 and Chromosome 21
| Chr region* | Primer name | Forward primer | Reverse primer | Position (bp) | Pr size† | Selected conc‡ |
|---|---|---|---|---|---|---|
| SERBINB5 | SERBINB5(1) | 5′-TATTTCACCTTCCGGTCCTG-3′ | 5′-GTTGTCTGCACAGCTTCCAA-3′ | 59294886 to 59295011 | 126 bp | 300 nmol/L |
| SERBINB5(2) | 5′-TACTTTTTGTGCCACCAACG-3′ | 5′-CAGGACCGGAAGGTGAAATA-3′ | 59294811 to 59294905 | 95 bp | 900 nmol/L | |
| SERBINB5(3) | 5′- TCCAGGTCTTTGTGCTCCTC-3′ | 5′-TACCCCACCTTGCTTACCTG-3′ | 59295190 to 59295275 | 86 bp | 300 nmol/L | |
| CHR18(A) | CHR18(A-1) | 5′-TAATGAGCTGTCGGCCTCTT-3′ | 5′-ATCTTCGATGTTCCCTGTGC-3′ | 55090284 to 55090425 | 142 bp | 300 nmol/L |
| CHR18(A-2) | 5′-TGTGCCTCTCCCTTGAGACT-3′ | 5′-AAATTGCAGCCAATGCTTCT-3′ | 55090427 to 55090524 | 98 bp | 300 nmol/L | |
| CHR18(A-3) | 5′-CGTGAATTCCGAGAAGCATT-3′ | 5′-GGCAAGGTCAACCTACCAGA-3′ | 55090494 to 55090605 | 112 bp | 300 nmol/L | |
| CHR21(A) | CHR21(A1) | 5′-GCTGGACCAGAAAGTGTTGAG-3′ | 5′-GTGTGCTGCTTTGCAATGTG-3′ | 39279856 to 39280004 | 149 bp | 300 nmol/L |
| CHR21(A2) | 5′-AAACACCGGGTGATAAGCAG-3′ | 5′-GGCCACTCACGCTCTTTTTA-3′ | 39279723 to 39279841 | 119 bp | 300 nmol/L | |
| CHR21(B) | CHR21(B1) | 5′-GATTGGTGTGTTTGGACCAG-3′ | 5′-AGAGGCAAGAGCAGAAACCA-3′ | 44161027 to 44161157 | 131 bp | 900 nmol/L |
| CHR21(B2) | 5′-GGTTTCTGCTCTTGCCTCTC-3′ | 5′-GGAGCAGCCTGAGGATCTTA-3′ | 44161139 to 44161279 | 141 bp | 300 nmol/L | |
| CHR21(B3) | 5′-GGTCGAGTTTTTGGTGGTGT-3′ | 5′-CCACCGTCACTGTTCCTAGA-3′ | 44161178 to 44161323 | 146 bp | 300 nmol/L | |
| CHR21(B4) | 5′-CCTCGTGCTCGTGTCTGTAT-3′ | 5′-GAGGAAACAGCTTGGCTCTG-3′ | 44161239 to 44161371 | 133 bp | 300 nmol/L | |
| CHR21(C) | CHR21(C1) | 5′-TAAGGTGGATCCGTTTGAGG-3′ | 5′-TTCGGGCTTTCAGTTAGGTG-3′ | 33320544 to 33320681 | 138 bp | 450 nmol/L |
| CHR21(C2) | 5′-CGTCCCCCTCGCTACTATCT-3′ | 5′-CAACGCTCCCTGAAATAACC-3′ | 33320716 to 33320829 | 114 bp | 300 nmol/L | |
| CHR21(C3) | 5′-CTGTTGCATGAGAGCAGAGG-3′ | 5′-CGTCCCCCTCGCTACTATCT-3′ | 33320735 to 33320829 | 95 bp | 900 nmol/L | |
| CHR21(D) | CHR21(D1) | 5′-TGTGCAGGATATTTGGCAAG-3′ | 5′-CTGTGCCGGTAGAAATGGTT-3′§ | 42189555 to 42189683 | 129 bp | 300 nmol/L |
| CHR21(D2) | 5′-TGCAGGATATTTGGCAAGGT-3′ | 5′-CTGTGCCGGTAGAAATGGTT-3′§ | 42189557 to 42189683 | 127 bp | 450 nmol/L | |
| CHR21(D3) | 5′-CACAGCACTGTCAGGAGGAA-3′ | 5′-GTCCTAGGAGTGCAGCCTGT-3′¶ | 42189223 to 42189343 | 121 bp | 300 nmol/L | |
| CHR21(D4) | 5′-CAGCACTGTCAGGAGGAACA-3′ | 5′-GTCCTAGGAGTGCAGCCTGT-3′¶ | 42189225 to 42189343 | 119 bp | 300 nmol/L | |
| CHR21(EI) | CHR21(EI-1) | 5′-TGAATCAGTTCACCGACAGC-3′ | 5′-GAAACAACCTGGCCATTCTC-3′ | 42355712 to 42355815 | 104 bp | 900 nmol/L |
| CHR21(EI-2) | 5′-GGCCAGGTTGTTTCAGATTG-3′ | 5′-TTCCGGCAGAGTTTATTTGG-3′ | 42355802 to 42355908 | 107 bp | 300 nmol/L | |
| CHR21(EII) | CHR21(EII-1) | 5′-CCGTTATATGGATGCCTTGG-3′ | 5′-AAACTGTTGGGCTGAACTGC-3′ | 42357215 to 42357341 | 127 bp | 750 nmol/L |
| CHR21(H) | CHR21(H1) | 5′-ACAGCGACGTGATCAACACT-3′ | 5′-CGCACTTACCCCTGACAAAT-3′ | 32268803 to 32268909 | 107 bp | 150 nmol/L |
| CHR21(H2) | 5′-CCACATCCTGGCCATCTACT-3′ | 5′-TTCCACAGACAGCAGAGACG-3′ | 32268843 to 32268943 | 101 bp | 300 nmol/L | |
| CHR21(I) | CHR21(I1) | 5′-TGAGCTCACAGGTCTGGAAA-3′ | 5′-CCCCACAGGGTTCTGGTAAT-3′ | 44079235 to 44079322 | 88 bp | 300 nmol/L |
| CHR21(I2) | 5′-CCCTGTGGGGTTTTTATTGAT-3′ | 5′-AGGTTTGTGAGGGTCCATGA-3′ | 44079313 to 44079415 | 103 bp | 300 nmol/L | |
| CHR21(I3) | 5′-CATGGACCCTCACAAACCTC-3′ | 5′-GTGGTCTGGGTGTGGAGAAT-3′ | 44079397 to 44079535 | 139 bp | 300 nmol/L |
The primer characteristics for the regions tested on chromosome 18 and chromosome 21.
*
Chromosomal region.
†
Product size.
‡
Selected concentration.
§ and ¶
Common primers.